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Introduction
Depression is a common condition, with a lifetime prevalence around 10% in Canada. 1 Major depression has negative consequences on individuals' quality of life, physical health, social relationships and employment. 2 Depression increases the risk of suicide and represents an important economic burden to society. 2 Antidepressant drug treatment (ADT), alone or in combination with psychotherapy, is recommended by the Canadian Network for Mood and Anxiety Treatments (CANMAT) for a minimum 
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Original research duration of 8 months. 2, 3 However, a large proportion of individuals show suboptimal adherence to ADT. In previous studies, 37% to 72% [4] [5] [6] [7] ceased treatment within 6 months, with up to 27% to 42% 4, 6, 7 of patients having ceased their treatment within the first month. Factors associated with treatment cessation include lack of confidence in ADT efficacy, fear of dependency, side effects at treatment initiation, less severe depressive symptoms at diagnosis, feeling better over time and inadequate support from the prescribing physician. [8] [9] [10] Community pharmacists are among the most accessible health professionals and have the potential to play a decisive role in optimizing patients' use of ADT. [11] [12] [13] Over the past 30 years, the role of community pharmacists has shifted from dispensing drugs to engaging in a pharmaceutical care approach that is centred on monitoring patient side effects, drug interactions, adherence and therapeutic objectives.
14 Few qualitative 12, 15 or quantitative 16, 17 studies have explored the experiences and expectations that ADT patients have with community pharmacists. Our team is currently conducting a series of studies 11, 13 to develop a community pharmacistbased intervention aimed at improving patients' experiences with and adherence to ADT. The objectives of this qualitative study were to 1) explore patients' experiences with the services that community pharmacists provide for ADT and 2) identify potential avenues for improving pharmacists' services within the context of ADT.
Methods
We conducted a qualitative descriptive exploratory study using semi-structured interviews. . We used a mixed inductive and deductive approach to develop codes. Initial codes were based on scientific literature, the objectives of the study, the conceptual framework and the interview guide. Additional codes and modifications emerged from the corpus. 18, 19 Since the credibility of analysis increases with intercoder fidelity, 2 members of the research team (A.N., MA student in community health, and L.G., PhD in health education) independently coded 6 interviews until a consensus was obtained on the codebook. 20 The remaining interviews were coded by A.N. through ongoing discussions with the research team. The sample size was not set a priori, and recruitment stopped after 14 interviews. This number was deemed sufficient given the overall consistency of the narratives and because no major new ideas had emerged from the last 3 interviews, indicating that data saturation had been achieved. 20 This study was approved by the ethics committees of the Centre de santé et des services sociaux de la Ville-Capitale and the CHU de Québec-Université Laval. All participants gave written consent to participate in this study and received $50 compensation.
Results

Participants' characteristics and experience with ADT
A total of 14 participants were recruited and interviewed (Table 1) . Ten participants were
KnowleDge Into PrActIce
• Patients who are prescribed an antidepressant drug treatment perceived that pharmacists are mainly involved at time of treatment initiation and that pharmacists' support consists mainly of providing information.
• Patients recommended that pharmacists provide more proactive counselling throughout the antidepressant drug treatment rather than passively waiting for patients to ask questions.
• Patients also recommended that the physical layout of pharmacies should better guarantee the confidentiality of discussions.
Original research recruited in a local health centre while 4 participants were recruited in a community-based organization. Most participants were women (n = 11), were younger than 40 years (n = 9), had obtained a college degree or higher (n = 9) and had a paid job at time of the interview (n = 9). Regarding ADT, 5 participants had received ADT in the past for a previous episode of depression. For the current episode of depression, 9 participants had received their ADT prescription less than 7 months before the interview and 5 participants between 7 and 12 months. All participants had initiated their ADT. Most participants reported that they questioned whether to initiate ADT after it was prescribed. They explained how several factors influenced their decision to take ADT, such as their personal evaluation of their health, the extent to which they recognized themselves as clinically depressed, their perceived need for medication and the physician's level of engagement when listening to their story and providing information. Three participants waited several weeks before starting their ADT, explaining how they needed some time to accept the diagnosis and medication.
At the time of the interviews, all participants were still taking their medication. However, a woman reported that she had prematurely stopped an ADT that had been prescribed for a past episode of depression. Even if participants were adherent to ADT, they periodically debated whether to continue with treatment. The temptation to cease ADT was especially high during the first weeks of treatment when participants were experiencing side effects but had not yet perceived any beneficial effects. Once beneficial effects had set in and the individuals had reengaged in normal activities, participants reported feeling better. These individuals often felt as though they no longer needed medication. Overall, participants took their ADT on a daily basis, but most reported that they sometimes forgot, skipped doses or did not take their ADT at the same time each day because they felt better or there were disruptions to their routine.
Perceptions of community pharmacists' actual and expected role
During data analysis, the research team identified 2 major dimensions that characterize what patients perceive to be the actual role of community pharmacists within the context of ADT: 1) pharmacists' support is focused on treatment initiation, primarily the first and second refills, and 2) pharmacists' support consists mainly of providing information. Interviews also led to the identification of patients' expectations of community pharmacists.
Pharmacists' support is focused on treatment initiation and first or second refills. When discussing their first encounter with community pharmacists, participants praised the excellent service that was provided. Participants reported feeling welcomed, reassured, listened to and, above all, not stigmatized for taking ADT. They also felt informed and appreciated that their questions were answered. "She [the pharmacist] took her time with me to be warm, to reassure me, to tell me I was taking an important step . . . it made all the difference to me" (participant 5). Patients often experienced this type of support at the time of treatment initiation (when patients are usually uncertain about ADT) and during the first or second refill (when temptation to stop treatment is highest because of side effects). Unless it was requested, they had no further encounters with pharmacists throughout the remainder of the treatment course. "It's just like going to buy candies. I get there, I give her my paper, she [the pharmacy technician] says, 'Thanks, it'll be ready in 2 minutes'" (participant 11).
Pharmacists' support consists mainly in providing information. Pharmacists were described as drug experts and a resource for information on taking ADT. This information complemented what had been said by the prescriber. "I feel like I'm getting a second opinion, I feel like the pharmacist knows the drug better" (participant
MIse en PrAtIQUe Des connAIssAnces
• les patients à qui l'on avait prescrit un traitement médicamenteux antidépresseur avaient le sentiment que les pharmaciens sont principalement présents à l'instauration du traitement et que le soutien qu'ils offrent se limite principalement à l'apport d'information.
• les patients ont recommandé que les pharmaciens offrent proactivement des conseils tout au long du traitement antidépresseur plutôt que d'attendre passivement que les patients posent des questions.
• les patients ont aussi recommandé que l'organisation physique des pharmacies assure la confidentialité des discussions. Original research how discussions on sensitive topics occurred at the pharmacy counter. This layout lacked confidentially and negatively affected participants' ability to speak freely. None of the participants had ever used a private consulting room. "It should be more discreet . . . everyone can hear. . . . You know, there's the lady next to you looking for her vitamin D" (participant 4). The second expectation was that pharmacists would provide proactive counselling throughout the duration of ADT treatment. Patients explained how pharmacists focused their interventions at treatment initiation and during first weeks of treatment. While patients were aware that pharmacists were available throughout the remainder of the treatment course, they did not always know what questions to ask. "Maybe a little follow-up, maybe not each time I'm there, to ask me if it's going well . . . as patients, we can always ask, but sometimes we forget to or sometimes we don't know exactly what to ask" (participant 1). Patients recommended that pharmacists assess the situation regularly so that important topics might arise naturally during discussion. "I wasn't able to ask for help. But if the pharmacist showed an interest in knowing how it was going . . . it would have encouraged me to ask for more services or advice" (participant 9).
Participants discussed other unmet expectations and suggested several services that pharmacists could provide to improve their experience with and adherence to ADT. These include a reminder email before each refill or a small 2-hour group education session. However, nothing was mentioned frequently enough to suggest a consensus. Participants were also unconvinced that the suggested services would result in a real improvement.
Discussion
Participants using ADT expressed a high degree of satisfaction with the services provided by community pharmacists. Pharmacists were described as drug experts and a resource for information that was complementary to what had been provided by prescribers. Participants appreciated pharmacists' welcoming attitude and their nonjudgmental listening skills. Patients received support from pharmacists at treatment initiation as well as during the first weeks of treatment. These are times when uncertainties are at their highest and managing side effects can be difficult.
Participants recommended that pharmacists offer more consistent support throughout the treatment period, when encounters with health professionals may be infrequent. Although patients reevaluate their decision to take ADT throughout the treatment course, pharmacists focus their efforts on the first encounters. The problem of timing in counselling has also been raised in earlier studies 12, 15 and is consistent with concerns that patients may have regarding the long-term side effects of ADT as well as their constant questioning of the need to continue treatment. 21, 22 If pharmacists passively wait for patients to ask questions after the second refill, they may miss important opportunities to enhance patient experience with and use of ADT. 23, 24 Another unmet expectation of participants was the lack of confidentiality at the pharmacy counter, which hindered their ability to speak freely. Although it has been reported elsewhere that pharmacists are aware of this barrier 16, 25, 26 and use strategies to overcome it-such as taking consumers to a quiet area of the pharmacy or a counselling room 27, 28 -the privacy of discussions on ADT remains a major issue for patients and pharmacists. 15, 26, [29] [30] [31] Recommendations for improving the privacy of discussions and increasing the number of encounters offered by pharmacists over the course of treatment are even more important given that stigma associated with depression may cause the patient discomfort and decrease support-seeking behaviours. [22] [23] [24] [32] [33] [34] Many participants had difficulty envisioning what pharmacists could do to improve their experience with ADT. This was, in part, because they perceived pharmacists' role to be limited to providing information and dispensing drugs. Participants instead relied on physicians to monitor their experience with ADT. These findings are consistent with results of other studies where patients on ADT 12, [15] [16] [17] or other mental health medications 35 perceived the provision of information to be the main contribution of pharmacists, with the difference that patients in the present study did not underline major unmet information needs. 12, [15] [16] [17] These findings are also in line with our previous study conducted among pharmacists, 11 who explained that their practice mainly focused on providing information, verifying drug safety and ensuring tolerability management at the first or second refill. This underscores how the ongoing monitoring 
Conclusion
This qualitative research should help improve our understanding of ADT patients' experience with pharmacists and ultimately provide clues for improving the practice of community pharmacists. Our findings have generated hypotheses that could be addressed in future quantitative studies conducted among a larger and more diverse group of patients with ADT. These findings could also be used in the development of questionnaires to assess dimensions of community pharmacy services that are important from the perspective of patients. In addition, they could inform the development of interventions aimed at enhancing patients' experience with community pharmacists-thus optimizing the use of ADT. Finally, these findings could inform the current debate surrounding pharmacy services and mental health patients as they raise issues on the frequency, timing and content of encounters as well as the physical layout of pharmacies. ■
